|
PRESS RELEASE - 12/09/2008
Intralytix awarded patent by USPTO for Bacteriophage
treatment of colonization by pathogen bacteria, including MRSA
Baltimore, Maryland U.S.A. – December 9, 2008 - - Intralytix,
Inc., announced today that it has been issued a patent by the
U.S. Patent & Trademark Office covering the use of
bacteriophages to reduce the risk of bacterial infection in
persons colonized with pathogenic bacteria including MRSA. The
patent broadly relates to the administration of compositions
containing bacteriophages to individuals colonized with
pathogenic bacteria in order to prevent the development of
bacterial infections. The claims cover the general method, means
and routes of administration, and specific cases including MRSA.
Nasal colonization of patients and healthcare personnel by MRSA
frequently leads to serious infection. The Center for Disease
Control estimates that 53 million people in the US are colonized
with MRSA. Over 2 million people contract staph infections in
hospitals each year. The claimed methods covered by the patent
are particularly important for preventing life-threatening
bacterial infections, treating immunocompromised patients
(including patients undergoing cancer chemotherapy), and
reducing the incidence of antibiotic resistant infections. The
patent covers the use of key Intralytix products, including a
nasal bacteriophage spray to significantly reduce or eliminate
colonization by Staphylococcus aureus, including MRSA.
John Vazzana, CEO, speaking for the company said, “Bacterial
infection of immunocompromised and seriously ill patients, as
well as antibiotic resistant infections are serious problems in
today’s world. We are excited that our technology has been
recognized as an innovative approach to help solve these
problems. We look forward to bringing this technology to
market.”
Intralytix, Inc. is a biotechnology company focused on improving
human health through the development and commercialization of
innovative products for food safety and human therapeutics using
its core bacteriophage technology platform.
For more information, contact John Woloszyn (410-625-0300 /
jwoloszy@intralytix.com) or Dr. Alexander Sulakvelidze
(410-625-2533 /
asulakvelidze@intralytix.com).
Intralytix, Inc.
701 East Pratt Street
Baltimore, MD 21202
www.intralytix.com
|
